Overall rank by patents
#25,692
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 2 technology areas, active 2015–2017. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H04B (TRANSMISSION).
The verdict
Aoptix holds 10 US patents across 2 technology areas, rank #25,692 of 50,000 tracked assignees.
Aoptix Technologies, Inc. has been granted 10 US utility patents between 2015 and 2017, placing Aoptix Technologies, Inc. at rank #25,692 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.8 claims per patent with primary concentration in H04B (TRANSMISSION). As a US Corporation, Aoptix Technologies, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Aoptix sits between ANP Technologies, Inc. (10 patents, rank #25,688) and APOS Medical Assets Ltd. (10 patents, rank #25,696) - the closest US assignees by grant volume. The composite Innovation Score of 25.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 10 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aoptix Technologies, Inc.'s 20.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aoptix Technologies, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ANP Technologies, Inc.
10 patents
ANT FINANCIAL (HANG ZHOU) NETWORK TECHNOLOGY CO., LTD.
10 patents
ANTHOGYR
10 patents
AO ETHER CORPORATION
10 patents
APANA Inc.
10 patents
APEM
10 patents
APHP (ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS)
10 patents
APOS MEDICAL ASSETS LTD.
10 patents
AOptix Technologies, Inc.
10 patents
What this shows Aoptix holds 10 patents at rank #25,692, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Aoptix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 82% higher than 18% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 50.0% |
| 2016 | 4 | 40.0% |
| 2017 | 1 | 10.0% |
Top 2 of 2 technology areas
Overall rank by patents
#25,692
Across all tracked assignees
25.8 out of 100
How to use this portfolio
Aoptix's 10 grants land it in the top 82% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.